| First Author | Ryu DK | Year | 2021 |
| Journal | Biochem Biophys Res Commun | Volume | 578 |
| Pages | 91-96 | PubMed ID | 34547629 |
| Mgi Jnum | J:335908 | Mgi Id | MGI:6792439 |
| Doi | 10.1016/j.bbrc.2021.09.023 | Citation | Ryu DK, et al. (2021) The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun 578:91-96 |
| abstractText | The SARS-CoV-2 variant is rapidly spreading across the world and causes to resurge infections. We previously reported that CT-P59 presented its in vivo potency against Beta variants, despite its reduced activity in cell experiments. Yet, it remains uncertain to exert the antiviral effect of CT-P59 on Gamma, Delta and its associated variants (L452R). To tackle this question, we carried out cell tests and animal studies. CT-P59 showed neutralization against Gamma, Delta, Epsilon, and Kappa variants in cells, with reduced susceptibility. The mouse challenge experiments with Gamma and Delta variants substantiated in vivo potency of CT-P59 showing symptom remission and virus abrogation in the respiratory tract. Collectively, cell and animal studies showed that CT-P59 is effective against Gamma and Delta variants infection, hinting that CT-P59 has therapeutic potential for patients infected with Gamma, Delta and its associated variants. |
